Vanguard Personalized Indexing Management LLC Increases Stock Position in AbbVie Inc. $ABBV

Vanguard Personalized Indexing Management LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 283,988 shares of the company’s stock after buying an additional 10,249 shares during the period. AbbVie accounts for 0.7% of Vanguard Personalized Indexing Management LLC’s investment portfolio, making the stock its 19th biggest holding. Vanguard Personalized Indexing Management LLC’s holdings in AbbVie were worth $65,783,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $4,288,200,000. Laurel Wealth Advisors LLC grew its stake in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after buying an additional 5,675,095 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after buying an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its position in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after acquiring an additional 2,753,312 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 0.5%

Shares of AbbVie stock opened at $219.21 on Monday. The company’s fifty day simple moving average is $225.60 and its two-hundred day simple moving average is $217.60. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market cap of $387.42 billion, a P/E ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ABBV shares. Bank of America boosted their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Citigroup reduced their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a report on Tuesday, January 13th. Finally, Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.